Stanford University
Showing 641-650 of 13,029 Results
-
Julie Baker
Professor of Genetics
Current Research and Scholarly InterestsWe examine how cells communicate and function during fetal development. The work in my laboratory focuses on the establishment of specific cell fates using genomics to decipher interactions between chromatin and developmental signaling cascades, between genomes and rapidly evolving cell types, and between genomic copy number variation and gene expression. In recent years we have focused on the vastly understudied biology of the trophoblast lineage, particularly how this lineage evolved.
-
Justin Nathaniel Baker
Deborah E. Addicott - John A. Kriewall and Elizabeth A. Haehl Family Professor of Pediatrics
BioAs a Pediatric Oncologist, Palliative Care Physician, and Phase I and End– of– Life Care Clinical Investigator, I am intimately aware of the distress experienced by children with advanced cancer and the ethical and end– of– life/bereavement issues surrounding their disease progression. I currently serve as the Chief of the Division of Quality of Life and Pediatric Palliative Care here at Stanford, as well as the Director of the Quality of Life for All (QoLA) Program. Additionally, I serve as the Associate Chief Quality Officer for Patient Experience and Holistic Care. In my past career at St Jude, I served as the Director of our large Pediatric Hematology/Oncology Fellowship Program for more than a decade. My research interests include ethical considerations surrounding enrollment in Phase I clinical trials, AYA palliative oncology care, end– of– life decision making, grief and bereavement, integrating palliative care into the ongoing care of children with cancer as well as patient– reported outcomes and pain and symptom control in the context of pediatric oncology care. I have received significant extramural funding for my research, and I have participated in dozens of studies related to pediatric palliative care. I have authored ~300 academic works on a broad array of palliative care subjects. In sum, I am a recognized global expert and leader in the field of Pediatric Palliative Care.
-
Laurence Baker
Josephine Knotts Knowles Professor of Human Biology, Senior Fellow at the Stanford Institute for Economic Policy Research and Professor, by courtesy, of Economics
On Partial Leave from 2026-09-01 To 2026-10-31Current Research and Scholarly InterestsDr. Baker's research is in the area of health economics, and focuses on the effects of financial incentives, organizational structures, and government policies on the health care delivery system, health care costs, and health outcomes.
-
Matthew C. Baker, MD MS
Associate Professor of Medicine (Immunology and Rheumatology)
BioDr. Baker is an Associate Professor of Medicine and Associate Division Chief in the Division of Immunology and Rheumatology at Stanford University. He is an internationally recognized expert in IgG4-related disease and is the Co-Founder and Co-Director of the Stanford Multidisciplinary Sarcoidosis Program. Dr. Baker received his bachelor's degree from Pomona College, his medical degree from Harvard Medical School, and a master's degree in Epidemiology and Clinical Research from Stanford University. He completed his residency in Internal Medicine at Massachusetts General Hospital and his fellowship in Rheumatology at Stanford University.
Dr. Baker's research program spans clinical trials, epidemiology, and translational science with the goal of accelerating the development of innovative therapies for immune-mediated diseases. He has designed and led investigator-initiated and industry-sponsored clinical trials in IgG4-related disease, sarcoidosis, Sjögren's disease, and rheumatoid arthritis. His epidemiologic research focuses on defining disease mechanisms, identifying novel therapeutic targets, and repurposing existing medications, including for the treatment of osteoarthritis.
Dr. Baker is also the Co-Founder and Co-Director of the Stanford Immune Reset Program, an interdisciplinary initiative dedicated to advancing transformative therapies with curative potential for autoimmune diseases, including T-cell engagers and in vivo CAR T-cell therapies.
